Comprehensive monitoring of the regulation of CPI and costimulatory molecules after administration of immunomodulatory antibodies (anti-PD1/PD-L1, anti-CTLA-4, anti-OX40, etc.)and cancer vaccines should help to guide the selection of the best combination and timing of this therapy. The gene discussed is TNFRSF4; the disease is cancer.